Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC

Lung cancer, increased survival with amivantamab plus lazertinib

By Victoria Damasceno (Folhapress) – A new treatment for lung cancer that involves the combination of two drugs has reduced by 25% the chances of death from a type of disease in the metastatic or advanced stage that mainly affects women and non-smokers. The side effects, however, are greater and more toxic. This is the combination of […]

Setting the Stage: Immunotherapy’s Impact and EMPOWER-Lung 1 Study Design

Panelists discuss how over the last five years, immunotherapy, particularly PD-1 inhibitors, has revolutionized advanced non-small cell lung cancer (NSCLC) treatment, offering promising first-line therapy options. Prior to the EMPOWER-Lung 1 study, PD-1 inhibitors showed improved survival outcomes as monotherapy. Treatment considerations have since evolved to incorporate patient-specific factors, optimizing therapy based on individual characteri…

Big Survival Gain in EGFR-Mutant NSCLC

PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib in advanced epidermal growth factor receptor (EGFR)-mutant non–small cell lung cancer (NSCLC). More specifically, the combination led to a statistically significant and clinically meaningful reduction in mortality compared […] The post Big Survival Gain i…

New results from studies presented at the European Congress of Lung Cancer (ELCC) 2025, held from 26 to 29 March, demonstrate the role of Tagrisso (osimertinib) of Astrazeneca as monotherapy and as an option for new therapeutic combinations in different stages and contexts of non-small cell lung cancer (NCLC) with epidermal growth factor receptor mutation (EGFRm). The highlights are: • Phase III LAURA trial in Stage III non-resectable EGFRm CPNM…

Amivantamab plus lazertinib shows survival benefit in lung cancer

Janssen drug combination extends life expectancy during trial